The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer. The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction. Here, we report a case of recurrent intestinal obstruction in a pat...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2014-01-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/358124 |
| _version_ | 1831753089499004928 |
|---|---|
| author | Willem Lybaert |
| author_facet | Willem Lybaert |
| author_sort | Willem Lybaert |
| collection | DOAJ |
| description | Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer. The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction. Here, we report a case of recurrent intestinal obstruction in a patient with adenocarcinoma. Although the obstruction was resolved after 3 days of treatment with octreotide, new episodes of obstruction occurred, resulting in a delay of the chemotherapy treatment. After 3 episodes of obstruction, we initiated treatment with a longer-acting somatostatin analogue, lanreotide Autogel® 120 mg, administered once every 4 weeks. The treatment with lanreotide Autogel is being continued, allowing for continuation of the chemotherapy without further episodes of intestinal subocclusion or obstruction. Until November 2013, the patient received eighteen 4-weekly injections of lanreotide Autogel and did not report side effects. This case report demonstrates the successful treatment of intestinal obstruction with lanreotide Autogel in a patient with adenocarcinoma. |
| first_indexed | 2024-12-21T23:14:52Z |
| format | Article |
| id | doaj.art-225bfb823a4f4a67820f20360b273503 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-21T23:14:52Z |
| publishDate | 2014-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-225bfb823a4f4a67820f20360b2735032022-12-21T18:46:56ZengKarger PublishersCase Reports in Oncology1662-65752014-01-0171434610.1159/000358124358124The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with AdenocarcinomaWillem LybaertIntestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer. The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction. Here, we report a case of recurrent intestinal obstruction in a patient with adenocarcinoma. Although the obstruction was resolved after 3 days of treatment with octreotide, new episodes of obstruction occurred, resulting in a delay of the chemotherapy treatment. After 3 episodes of obstruction, we initiated treatment with a longer-acting somatostatin analogue, lanreotide Autogel® 120 mg, administered once every 4 weeks. The treatment with lanreotide Autogel is being continued, allowing for continuation of the chemotherapy without further episodes of intestinal subocclusion or obstruction. Until November 2013, the patient received eighteen 4-weekly injections of lanreotide Autogel and did not report side effects. This case report demonstrates the successful treatment of intestinal obstruction with lanreotide Autogel in a patient with adenocarcinoma.http://www.karger.com/Article/FullText/358124Intestinal obstructionAdenocarcinomaSomatostatin analogueLanreotide Autogel® |
| spellingShingle | Willem Lybaert The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma Case Reports in Oncology Intestinal obstruction Adenocarcinoma Somatostatin analogue Lanreotide Autogel® |
| title | The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma |
| title_full | The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma |
| title_fullStr | The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma |
| title_full_unstemmed | The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma |
| title_short | The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma |
| title_sort | use of lanreotide autogel r in the treatment of intestinal obstruction in a patient with adenocarcinoma |
| topic | Intestinal obstruction Adenocarcinoma Somatostatin analogue Lanreotide Autogel® |
| url | http://www.karger.com/Article/FullText/358124 |
| work_keys_str_mv | AT willemlybaert theuseoflanreotideautogelinthetreatmentofintestinalobstructioninapatientwithadenocarcinoma AT willemlybaert useoflanreotideautogelinthetreatmentofintestinalobstructioninapatientwithadenocarcinoma |